1-palmitoyl-2-(8'-N-Fmoc-amino-3',6'-dioxaoctanoyl)-sn-glycerophosphocholine | 1264195-16-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1-palmitoyl-2-(8'-N-Fmoc-amino-3',6'-dioxaoctanoyl)-sn-glycerophosphocholine
• CAS: 1264195-16-5
• 化学式: C₄₅H₇₁N₂O₁₂P
• 分子量: 863.039
• InChiKey: MXGORSRGTMAPQR-DIPNUNPCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  60.0
• 可旋转键数：
  34.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  167.98
• 氢给体数：
  1.0
• 氢受体数：
  12.0

反应信息

• 作为反应物：
  描述：

  1-palmitoyl-2-(8'-N-Fmoc-amino-3',6'-dioxaoctanoyl)-sn-glycerophosphocholine 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 氯仿 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Synthesis of oligo(ethylene glycol) substituted phosphatidylcholines: Secretory PLA2-targeted precursors of NSAID prodrugs

  摘要：

  A series of new phosphatidylcholine analogues with structurally modified sn-2-substituents have been prepared. The synthetic compounds include oligo(ethylene glycol) derivatives with chain-terminal pharmacophores that upon catalytic hydrolysis by phospholipase A(2) yielded a series of oligo(ethylene glycol)-conjugates of the respective drugs. The approach here outlined may open a new way to employ OEG derivatives of phospholipids for therapeutic applications as secretory PLA(2)-targeted precursors of prodrugs. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

  DOI：

  10.1016/j.chemphyslip.2009.10.001
• 作为产物：
  描述：

  8-N-Fmoc-amino-3,6-dioxaoctanoic acid 、 溶血磷脂酰胆碱(鸡蛋) 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 氯仿 为溶剂， 反应 6.0h， 以75%的产率得到1-palmitoyl-2-(8'-N-Fmoc-amino-3',6'-dioxaoctanoyl)-sn-glycerophosphocholine
  参考文献：
  名称：

  Synthesis of oligo(ethylene glycol) substituted phosphatidylcholines: Secretory PLA2-targeted precursors of NSAID prodrugs

  摘要：

  A series of new phosphatidylcholine analogues with structurally modified sn-2-substituents have been prepared. The synthetic compounds include oligo(ethylene glycol) derivatives with chain-terminal pharmacophores that upon catalytic hydrolysis by phospholipase A(2) yielded a series of oligo(ethylene glycol)-conjugates of the respective drugs. The approach here outlined may open a new way to employ OEG derivatives of phospholipids for therapeutic applications as secretory PLA(2)-targeted precursors of prodrugs. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

  DOI：

  10.1016/j.chemphyslip.2009.10.001